- Featured Product
- KD/KO Validated
PCSK9 Polyclonal antibody
PCSK9 Polyclonal Antibody for FC, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
Human, mouse, rat and More (1)
Applications
WB, IHC, IF, FC, ELISA
Conjugate
Unconjugated
Cat no : 27882-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | HepG2 cells, rat liver tissue, mouse liver tissue |
| Positive FC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Flow Cytometry (FC) | FC : 0.40 ug per 10^6 cells in a 100 µl suspension |
| Sample-dependent, check data in validation data gallery | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 5 publications below |
| IHC | See 3 publications below |
| IF | See 2 publications below |
Product Information
27882-1-AP targets PCSK9 in WB, IHC, IF, FC, ELISA applications and shows reactivity with Human, mouse, rat samples.
| Tested Reactivity | Human, mouse, rat |
| Cited Reactivity | human, rat, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | PCSK9 fusion protein Ag27254 相同性解析による交差性が予測される生物種 |
| Full Name | proprotein convertase subtilisin/kexin type 9 |
| Calculated molecular weight | 74 kDa |
| Observed molecular weight | 72-78 kDa, 62 kDa |
| GenBank accession number | NM_174936.3 |
| Gene symbol | PCSK9 |
| Gene ID (NCBI) | 255738 |
| RRID | AB_2918134 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for PCSK9 antibody 27882-1-AP | Download protocol |
| FC protocol for PCSK9 antibody 27882-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Biochimie High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats | ||
bioRxiv Effect of Total Sphingomyelin Synthase Activity on Low Density Lipoprotein Catabolism in Mice | ||
iScience Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer
| ||
FASEB J Exogenous hydrogen sulfide alleviates hepatic endoplasmic reticulum stress via SIRT1/FoxO1/PCSK9 pathway in NAFLD | ||
JACC Basic Transl Sci PCSK9 Promotes Hypoxia-Induced EC Pyroptosis by Regulating Smac Mitochondrion-Cytoplasm Translocation in Critical Limb Ischemia | ||
Oncol Lett PCSK9 promotes tumor cell proliferation and migration by facilitating CCL25 secretion in esophageal squamous cell carcinoma |
